Navigation Links
EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
Date:3/6/2008

ROCKVILLE, Md., March 6 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today reported results for the three months and twelve months ended December 31, 2007.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

For fiscal year 2007, revenues were $7.4 million versus $6.9 million for 2006. For the year ended December 31, 2007, the Company reported a net loss of ($23.4 million) or ($0.28) per share, versus ($50.9 million), or ($0.71) per share, for fiscal year 2006. As of December 31, 2007, the Company had cash and short-term investments of approximately $47.7 million.

Revenues for the fourth quarters ended December 31, 2007 and December 31, 2006 were both $3.9 million. The Company reported a net loss of ($4.0 million), or ($.05) per share for the three months ended December 31, 2007. This compares with a net loss of ($5.9 million), or ($0.08) per share for the fourth quarter 2006.

Dane R. Saglio, EntreMed Chief Financial Officer, commented, "Financial results for 2007 reflect an increase in both revenue and research and development expenses versus 2006. For the year, we recorded $7.4 million in royalty revenue, a small increase over 2006 royalty revenues of $6.9 million. While research and development expenses decreased in the fourth quarter, there was an increase of approximately $2 million for the full year as a result of the initiation of multiple Phase 2 trials for MKC-1 and Panzem(R) NCD, as well as the submission and acceptance of two IND filings in 2007. In addition to reporting our opera
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
2. EntreMed Appoints Senior Vice President of Research and Development
3. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
4. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
5. EntreMed to Present at BIO CEO and Investor Conference
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. QMed, Inc. Reports July Medicare SNP Enrollments
8. Phlo Affiliate Reports Expanded Coverage to Oregon Border
9. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Carrington Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Carahsoft and CDS Federal Services have ... at 2pm EST (11am PST), “Natural Language Processing: Converting ... how technology can turn raw, heterogeneous data into actionable ... The online webinar will last approximately one hour. , ...
(Date:1/14/2014)... pet owners drew up their lists of New Year,s resolutions for ... of my furry companion." Nowadays there are pet salons, dog and ... take the little canine or feline darlings along wherever mommy or ... pricey toys at the pet store. But anyone who has ever ...
(Date:1/14/2014)... DIEGO and BETHESDA, Md. ... are joining together with two institutes from the National ... reliable tools for bringing safer, more effective treatments to ... the National Center for Advancing Translational Sciences (NCATS) and ...
(Date:1/14/2014)... Jan. 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), ... commercializing innovative therapies addressing major unmet medical needs ... the Notice of Allowance from the United States ... RNAi compounds (sd-rxRNA®), for the treatment of fibrosis. ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... LAUSANNE, Switzerland, September 3 Debiopharm Group, ... with,a focus on the development of prescription drugs ... Life Sciences Award, to Dr Lluis,Quintana-Murci from the ... in the emerging field of evolutionary genetics of,infection. ...
... JERUSALEM, September 3 Oramed Pharmaceuticals,Inc. (OTC ... systems, announced today that Nadav Kidron, its Chief Executive,Officer, is ... Conference on Friday September 11, 2009 at 10:00 a.m. EDT. ... in New York City. , Nadav ...
... , , BEIJING, Sept. 3 ... President Chung Leik Kok, announced today the signing of two (2) ... and Chemical Co., Ltd. (Beijing Oil & Gas). Fauve Intertrade is ... Miami, Florida; and Kuala Lumpur, Malaysia - with offices opening in ...
Cached Biology Technology:The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection 2The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection 3Oramed Pharmaceuticals to Present at Rodman & Renshaw 11th Annual Healthcare Conference 2Fauve Intertrade Signs Major Energy Contracts in China 2
(Date:4/23/2014)... a newly coined term for novels and films which focus ... of Copenhagen shows how these fictions serve as a mental ... climate change and imagine other living conditions. , "Global ... the atmosphere; it is also a cultural phenomenon in which ... the films we see. And there are so many of ...
(Date:4/23/2014)... University of Exeter researcher has shed light on how ... in Australia,s remote outback have become reviled as pests ... of the Environment and Sustainability Institute at the University ... camel in Australia, from their historic role helping to ... as unwelcome "invader." , The deserts of the Australian ...
(Date:4/23/2014)... leading a 2 million Food Standards Agency (FSA) project ... and industry workers. , Norovirus outbreaks can rapidly ... batch of frozen strawberries infected 11,000 people in Germany, ... of which strains cause infection and which foods are ... , Researchers will produce data that will help the ...
Breaking Biology News(10 mins):Fiction prepares us for a world changed by global warming 2Fiction prepares us for a world changed by global warming 3How Australia got the hump with 1 million feral camels 2How Australia got the hump with 1 million feral camels 3
... States, (U.S.) predominance in science and technology (S&T) eroded ... China and South Korea--rapidly increased their innovation capacities. According ... Board (NSB), the policy making body of the National ... and Congress, the major Asian economies, taken together, now ...
... , This news release is available in ... transmission at the synapse between neurons is a highly complex, but ... voltage change, the so-called action potential, reaches the synaptic terminal in ... presynaptic neuron. This influx leads to a rise in the intracellular ...
... led by scientists from the University of California, San ... a protein that broadly regulates how genetic information transcribed ... ultimately translated into the myriad of proteins necessary for ... Cell Reports , help explain how a relatively ...
Cached Biology News:US lead in science and technology shrinking 2US lead in science and technology shrinking 3US lead in science and technology shrinking 4Loose coupling between calcium channels and sensors 2Global regulator of mRNA editing found 2
Human DPPII/QPP/DPP7 Biotinylated Affinity Purified PAb ENTREZ GeneID: 29952...
Human SorCS1 Affinity Purified Polyclonal Ab Protein Family: Neurotrophins...
Human Apolipoprotein B100 Affinity Purified Polyclonal Ab ENTREZ GeneID: 338...
hypertension-related calcium-regulated gene, mRNA...
Biology Products: